Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Dishman Carbogen Amcis Limited

DCAL · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹145.02

−₹4.40 (−2.94%)(1D)

₹128.5052 Week Range₹303.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

25/100

Valuation

0/100

Quality

9/100

Growth

55/100

Health

55/100

Momentum

18/100

Valuation
0
Quality
9
Growth
55
Health
55
Momentum
18

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Dishman Carbogen Amcis Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹145.02

Market cap

₹2,275 Cr

P/E ratio

139.44

P/B ratio

0.34

Dividend yield

Not available

ROE

Not available

RSI 14

41.08

1Y return

Not available

Dishman Carbogen Amcis Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Dishman Carbogen Amcis Limited (DCAL) stock page cover?

Dishman Carbogen Amcis Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for DCAL?

Dishman Carbogen Amcis Limited is currently shown with a delayed price near ₹145.02, P/E 139.44.

Does the DCAL page provide investment advice?

No. The DCAL page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

PANACEABIO

Panacea Biotec Limited · Healthcare

ZOTA

Zota Health Care LImited · Healthcare

SUPRIYA

Supriya Lifescience Limited · Healthcare

Factor Investing in India: Backtesting Value, Quality, and Low-Volatility Combos

Master factor investing in Indian equities. Explore 10-year historical return data for Quality, Value, Low Volatility, and multi-factor blends on Anvest.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Dishman Carbogen Amcis Limited is an India-based integrated contract development and manufacturing organization (CDMO) serving the global pharmaceutical and biotech industries. The company specializes in complex chemistry, including highly potent active pharmaceutical ingredients (APIs) and vitamin D analogues, offering services from research to commercial manufacturing.

BiotechnologyGlobal FootprintFounded:1983CEO/MD:Arpit VyasHQ:Ahmedabad, Gujarat, India

Business profile as of 2026-08-25

Business at a Glance

Other segments are Quats & Generics.

Revenue growth: +8.1%FY26 growth+6.7%3Y CAGR
EPS growth: +2861.9%FY26 growthN/M3Y CAGR
CFO / PAT: 5.04×FY26

What Looks Strong

Cash FlowOperating cash flow was 5.04× total net profit in FY26.
Balance SheetConservative capital structure with manageable leverage of 0.42× Debt/Equity.

What to Watch

ValuationThe shares trade at 139× trailing earnings; the multiple assumes sustained high growth and is sensitive to any slowdown.
TrendPrice is 20% below its 200-day moving average, indicating a weak long-term price trend.

Reports a single operating segment in its results filings.
The company generates revenue by providing contract research and manufacturing services (CRAMS) to pharmaceutical and biopharmaceutical clients.
This includes custom synthesis of active pharmaceutical ingredients (APIs) and intermediates, as well as offering comprehensive services from drug discovery support to commercial-scale manufacturing.

FY26 (consolidated): revenue ₹2,932 cr, up 8% from ₹2,712 cr in FY25; net profit ₹97.5 cr, about 30.1× the ₹3.2 cr in FY25.
FY26 (consolidated): operating cash flow ₹491 cr (5.0× net profit); debt/equity 0.42×.
Latest quarter to Jun 2026 (consolidated): revenue ₹678 cr (down 4% year on year); a net loss of ₹57.9 cr.